Suppressed T-Cell Receptor ζ Chain Expression and Cytokine Production in Pancreatic Cancer Patients

Cancer Research

Volumn 7, Issue , 2001, Pages

  Schmielau, Jan ^a   Nalesnik, Michael A ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN T CELL RECEPTOR, ZETA CHAIN; CA 15-3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA;

ADENOCARCINOMA; ARTICLE; BIOPSY; BIOSYNTHESIS; CHEMISTRY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN TUMOR; T LYMPHOCYTE; TIME;

ADENOCARCINOMA; BIOPSY; CA-15-3 ANTIGEN; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-4; MEMBRANE PROTEINS; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS;

EID: 0035294392     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Stein, J. A., Adler, A., Efraim, S. B., and Maor, M. Immunocompetence, immunosuppression, and human breast cancer. I. An analysis of their relationship by known parameters of cell-mediated immunity in well-defined stages of disease. Cancer (Phila.), 38:1171-1187, 1976.
2. Young, R. C., Corder, M. P., Haynes, H. A., and DeVita, V. T. Delayed hypersensitivity in Hodgkin's disease. Am. J. Med., 52: 63-72, 1972.
3. Fisher, R. I., DeVita, V. T., Jr., Bostick, F., Vanhaelen, C., Howser, D. M., Hubbard, S. M., and Young, R. C. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann. Intern. Med., 92: 595-599, 1980.
4. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 258: 1795-I798, 1992.
5. Gunji, Y., Hori, S., Aoe, T., Asano, T., Ochiai, T., Isona, K., and Saito, T. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T iymphocytes. Jpn. J. Cancer Res., 85: 1189-1192, 1994.
6. Kono, K., Ressing, M. E., Brandt, R. M., Melief C. J., Potkul, R. K., Andersson, B., Petersson, M., Kast, W. M., and Kiessling, R. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res., 2: 1825-1828, 1996.
7. Matsuda, M., Petersson, M., Lenkei, R., Taupin, J. L., Magnusson, I., Mellstedt, H., Anderson, P., and Kiessling, R. Alterations in the signaltransducing molecules of T cells and NK cells in colorectal tumorinfiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer, 61: 765-772, 1995.
8. Rabinowich, H., Banks, M., Reichert, T. E., Logan, T. F., Kirkwood, J. M., and Whiteside, T. L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin therapy. Clin. Cancer Res., 2: 1263-1274, 1996.
9. Reichert, T. E., Rabinowich, H., Johnson, J. T., and Whiteside, T. L. Immune cells in the tumor microenvironment. Mechanisms responsible for signaling and functional defects. J. Immunother., 21: 295-306, 1998.
10. Zea, A. H., Curti, B. D., Longo, D. L., Alvord, W. G., Strobl, S. L., Mizoguchi, H., Creekmore, S. P., O'Shea, J. J., Powers, G. C., Urba, W. J., et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res., 1: 1327-1335, 1995.
11. Ghosh, P., Sica, A., Young, H. A., Ye, J., Franco, J. L., Wiltrout, R. H., Longo, D. L., Rice, N. R., and Komschlies, K. L. Alteration in NFKB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res., 54: 2969-2972, 1994.
12. Elliott, L. H., Brooks, W. H., and Roszman, T. L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J. Immunol., 132:1208-1215, 1984.
13. Elsasser-Beile, U., Kolble, N., Grussenmeyer, T., Schultze-Seemann, W., Wetterauer, U., Gallati, H., Schulte Monting, J., and yon Kleist, S. Thl and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol., 19: 470-476, 1998.
14. Goto, S., Sato, M., Kaneko, R., Itoh, M., Sato, S., and Takeuchi, S. Analysis of Thl and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother., 48: 435-442, 1999.
15. Guilloux, Y., Viret, C., Gervois, N., Le Dréan E., Pandolfino, M-C., Diez, E., and Jotereau, F. Defective lymphokine production by most CD8 + and CD4 + tumor-specific T cell clones derived from human melanomaqnfiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol., 24: 1966-1973, 1994.
16. Nieland, J. D., Loviscek, K., Kono, K., Albain, K. S., McCall, A. R., Potkul, R. K., Fisher, S. G., Velders, M. P., Petersson, M., Kiessling, R., and Kast, W. M. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR ζ expression but are functionally impaired. J. Immunother., 21: 317-322, 1998.
17. Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Dominech, N., Magarian-Blander, J., and Barratt-Boyes, S. M. MUC-1 epithelial mucin-based immunity and cancer vaccines. Immunol. Rev., 145: 61-89, 1995.
18. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., and Lotze, M. T. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res., 63: 298-304, 1996.
19. Kruse, N., Pette, M., Toyka, K., and Rieckmann, P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J. Immunol. Methods, 210: 195-203, 1997.
20. Franco, J. L., Ghosh, P., Wiltrout, R. H., Carter, C. R. D., Zea, A. H., Momozaki, N., Ochoa, A. C., Longo, D. L., Sayers, T. J., and Komschlies, K. L. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res., 55: 3840-3846, 1995.
21. Klausner, R. D., Lippincott-Schwartz, J., and Bonifacino, J. S. The T cell antigen receptor: insights into organelle biology. Annu. Rev. Cell Biol., 6: 403-431, 1990.
22. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Caspase-mediated degradation of T-cell receptor ζ-chain. Cancer Res., 59: 1422-1427, 1999.
23. Pellegrini, P., Berghella, A. M., Beato, T. D., Cicia, S., Adorna, D., and Casciani, C. U. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother., 42: 1-8, 1996.
24. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., and Yves Blay, J. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today, 18: 493-497, 1997.
25. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., and Nagata, S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med., 186: 2045-2050, 1997.
26. von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Jöhnk, C., Henne-Bruns, D., Kremer, B., and Katthoff, H. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res., Suppl. 7: 925s-932s, 2001.
27. Zea, A. H., Ochoa, M. T., Ghosh, P., Longo, D. L., Alvord, W. G., Valderrama, L., Falabella, R., Harvey, L. K., Saravia, N., Moreno, L. H., and Ochoa, A. C. Changes in expression of the signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun., 66: 499-504, 1998.
28. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J. J., Kudoh, S., Klein, E., Bukowski, R. M., and Ochoa, A. C. Loss of T-cell receptor ζ chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.
29. Isakov, N., McMahon, P., and Altman, A. Selective post-transcriptional down-regulation of protein kinase C isoenzymes in leukemic T cells chronically treated with phorbol esters. J. Biol. Chem., 265: 2091-2097, 1990.
30. Fields, P. E., Gajewski, T. F., and Fitch, F. W. Blocked ras activation in anergic CD4 + T cells. Science (Washington DC), 271: 1276-1278, 1996.
31. Kang, S-M., Beverly, B., Tran, A-C., Broson, K., Schwartz, R. H., and Lenardo, M. J. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science (Washington DC), 257:1134-1138, 1992.
32. Mueller, D. L., Chiodetti, L., Bacon, P. A., and Schwartz, R. H. Clonal anergy blocks the response to IL-4, as well as the production of IL-2 in dual-producing helper T cell clones. J. Immunol., 147: 4118-4125, 1991.